Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same journal

Limited Deoxynucleoside Pools Underlie Cisplatin-Induced Neurotoxicity.

Cancer discovery·2026

Same journal

Chemically Induced Skin Tumors Arise from Upper Hair Follicle Stem Cells.

Cancer discovery·2026

Same journal

Retraction Casts Doubt on Timing Effects of Immunotherapy.

Cancer discovery·2026

Same journal

mtDNA Lineage Tracing Reveals Monocyte Fate Bias Prior to Tumor Infiltration.

Cancer discovery·2026

Same journal

Impact of vitamin D on the colon cancer immune microenvironment: results of a randomized clinical trial of preoperative vitamin D supplementation in patients with stage I-III colon cancer.

Cancer discovery·2026

Same journal

DNA, Peptide Vaccines Advance Against GBM.

Cancer discovery·2026

Search research articles

Related Experiment Video

Updated: Apr 19, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

TKIs may be option for Ph-like ALL

Cancer Discovery

|December 6, 2014

Summary

This summary is machine-generated.

A new subtype of acute lymphoblastic leukemia, Ph-like ALL, is driven by genetic changes activating kinase signaling. These alterations suggest potential vulnerability to tyrosine kinase inhibitors.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Experiment Videos

Last Updated: Apr 19, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Area of Science:

Hematology
Oncology
Molecular Biology

Background:

Acute lymphoblastic leukemia (ALL) is a significant hematologic malignancy.
A distinct subtype, Philadelphia chromosome-like ALL (Ph-like ALL), has been identified.
Ph-like ALL is characterized by genetic alterations that activate specific signaling pathways.

Discussion:

The identified genetic drivers in Ph-like ALL lead to aberrant kinase signaling.
Understanding these specific kinase alterations is crucial for targeted therapeutic strategies.

Key Insights:

Ph-like ALL harbors genetic changes that activate kinase signaling pathways.
These kinase-activating alterations present potential therapeutic vulnerabilities.

Outlook:

FDA-approved tyrosine kinase inhibitors may offer a targeted treatment approach for Ph-like ALL.
Further research is warranted to explore the efficacy and safety of TKIs in this patient population.